We are live on ! Find out more
HSTO

Histogen Inc. Common Stock

Delisted

HSTO was delisted on the 4th of October, 2023.

78 hedge funds and large institutions have $60.8M invested in Histogen Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

29% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 17

12% more call options, than puts

Call options by funds: $677K | Put options by funds: $606K

11% more funds holding

Funds holding: 7078 (+8)

6% more capital invested

Capital invested by funds: $57.5M → $60.8M (+$3.34M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
78
Holders Change
+8
Holders Change %
+11.43%
% of All Funds
1.94%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
22
Increased
22
Reduced
17
Closed
13
Calls
$677K
Puts
$606K
Net Calls
+$71K
Net Calls Change
+$174K

HSTO Hedge Fund Activity: Q3 2017 in Review

78 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Histogen Inc. Common Stock (HSTO) for Q3 2017, worth a combined $60.8M — up 5.8% from $57.5M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new HSTO positions and 13 closed out — a net gain of 9 holders — while 22 added to existing stakes and 17 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $1.66M. The largest seller was Bogle Investment Management, cutting an estimated $1.71M.

  • 78 institutional investors held Histogen Inc. Common Stock (HSTO) as of Q3 2017, up from 70 in Q2 2017.
  • Funds reported $60.8M of Histogen Inc. Common Stock stock for Q3 2017, up 5.8% quarter-over-quarter.
  • 22 funds opened new Histogen Inc. Common Stock positions in Q3 2017 and 13 closed out, a net change of +9 holders.
  • The largest Histogen Inc. Common Stock buyer in Q3 2017 was AQR Capital Management, an estimated $1.66M added.
  • The largest Histogen Inc. Common Stock seller in Q3 2017 was Bogle Investment Management, an estimated $1.71M sold.

Based on aggregated 13F filings for Q3 2017.